We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Innovation, Partnership Aid Genomic Health, Cost Woe Remains
Read MoreHide Full Article
On Dec 18, we issued an updated research report on Genomic Health Inc , a global cancer research company with its focus on advanced molecular diagnostics.
Genomic Health has been trading above the broader industryover the past three months. The stock has rallied 16.2% compared with the broader industry’s 11.4% decline. In fact the stock has skyrocketed over the past week on a couple of developments.
The market is particularly optimistic about Genomic Health’s recently announced outcomes from a series of 10 trials, which underscore the efficiency of the Oncotype DX Breast Recurrence Score test and the Oncotype DX DCIS Score test for breast cancer. Notably, Ductal carcinoma in situ, also known as DCIS, is the most common type of non-invasive breast cancer.
We are also upbeat about the company’s multi-year research collaboration agreement with Janssen Pharmaceuticals to evaluate the Oncotype DX Genomic Prostate Score (“GPS”) test for its prostate cancer drug pipeline. As part of the deal, Genomic Health will test samples from Janssen studies to examine the association of GPS results with clinical outcomes.
Overall, we are encouraged by the year-over-year rise in revenues, driven by solid performances in the United States and internationally. During the third quarter, international test volumes expanded 14%, representing 26% of the total test volumes in the period.
So far, Genomic Health has witnessed a healthy progress with regard to establishing coverage for its Oncotype DX breast cancer test. In 2018, Genomic Health expects several key catalysts to drive strong revenue growth. These catalysts include the anticipated implementation of both PAMA (Protecting Access to Medicare Act) reimbursement — at a higher level than the 2016 invasive breast rate — and AJCC (American Joint Committee on Cancer) staging criteria, which will be effective from January 2018.
Within the prostate cancer business, the Oncotype DX Genomic Prostate Score test received a positive Local Coverage Determination to expand Medicare coverage by Palmetto GBA. The company also made some positive developments for its Oncotype DX Breast Recurrence Score tests. In addition, it established a private coverage for the test in Germany.
On the flip side, revenues in the third quarter of 2017 lagged the Zacks Consensus Estimate due to disruption from the hurricanes in certain regions of the United States (estimated to have affected domestic test volumes by approximately 3%). The company’s rising operating losses also continue to be a huge concern. In addition, its sole reliance on profitability of Breast Oncotype DX test is a challenge to cope with. Above all, management’s decision not to issue any guidance has been discouraging too as it failed to provide us with any definite visibility about the company’s upcoming performance.
Zacks Rank & Key Picks
Genomic Health has a Zacks Rank #3 (Hold). A few better-ranked medical stocks are athenahealth, Inc. , Align Technology, Inc. (ALGN - Free Report) and Luminex Corporation . Notably, athenahealth, andAlign Technology sport a Zacks Rank #1 (Strong Buy) while Luminexcarries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
athenahealthhas a long-term expected earnings growth rate of 22.3%. The stock has rallied roughly 17.1% over a year.
Align Technologyhas a long-term expected earnings growth rate of 28.9%. The stock has gained 134.5% in a year.
Luminex has a long-term expected earnings growth rate of 16.3%. The stock has gained 4.6% in the past three months.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Image: Bigstock
Innovation, Partnership Aid Genomic Health, Cost Woe Remains
On Dec 18, we issued an updated research report on Genomic Health Inc , a global cancer research company with its focus on advanced molecular diagnostics.
Genomic Health has been trading above the broader industryover the past three months. The stock has rallied 16.2% compared with the broader industry’s 11.4% decline. In fact the stock has skyrocketed over the past week on a couple of developments.
The market is particularly optimistic about Genomic Health’s recently announced outcomes from a series of 10 trials, which underscore the efficiency of the Oncotype DX Breast Recurrence Score test and the Oncotype DX DCIS Score test for breast cancer. Notably, Ductal carcinoma in situ, also known as DCIS, is the most common type of non-invasive breast cancer.
We are also upbeat about the company’s multi-year research collaboration agreement with Janssen Pharmaceuticals to evaluate the Oncotype DX Genomic Prostate Score (“GPS”) test for its prostate cancer drug pipeline. As part of the deal, Genomic Health will test samples from Janssen studies to examine the association of GPS results with clinical outcomes.
Overall, we are encouraged by the year-over-year rise in revenues, driven by solid performances in the United States and internationally. During the third quarter, international test volumes expanded 14%, representing 26% of the total test volumes in the period.
So far, Genomic Health has witnessed a healthy progress with regard to establishing coverage for its Oncotype DX breast cancer test. In 2018, Genomic Health expects several key catalysts to drive strong revenue growth. These catalysts include the anticipated implementation of both PAMA (Protecting Access to Medicare Act) reimbursement — at a higher level than the 2016 invasive breast rate — and AJCC (American Joint Committee on Cancer) staging criteria, which will be effective from January 2018.
Within the prostate cancer business, the Oncotype DX Genomic Prostate Score test received a positive Local Coverage Determination to expand Medicare coverage by Palmetto GBA. The company also made some positive developments for its Oncotype DX Breast Recurrence Score tests. In addition, it established a private coverage for the test in Germany.
On the flip side, revenues in the third quarter of 2017 lagged the Zacks Consensus Estimate due to disruption from the hurricanes in certain regions of the United States (estimated to have affected domestic test volumes by approximately 3%). The company’s rising operating losses also continue to be a huge concern. In addition, its sole reliance on profitability of Breast Oncotype DX test is a challenge to cope with. Above all, management’s decision not to issue any guidance has been discouraging too as it failed to provide us with any definite visibility about the company’s upcoming performance.
Zacks Rank & Key Picks
Genomic Health has a Zacks Rank #3 (Hold). A few better-ranked medical stocks are athenahealth, Inc. , Align Technology, Inc. (ALGN - Free Report) and Luminex Corporation . Notably, athenahealth, andAlign Technology sport a Zacks Rank #1 (Strong Buy) while Luminexcarries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
athenahealthhas a long-term expected earnings growth rate of 22.3%. The stock has rallied roughly 17.1% over a year.
Align Technologyhas a long-term expected earnings growth rate of 28.9%. The stock has gained 134.5% in a year.
Luminex has a long-term expected earnings growth rate of 16.3%. The stock has gained 4.6% in the past three months.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>